Effect of endothelin-1 in man: pretreatment with nifedipine, with indomethacin and with cyclosporine A.
The rise in blood pressure following the intravenous administration of endothelin-1 remained unchanged in healthy male volunteers pretreated with either the calcium-channel antagonist nifedipine (10 mg orally), the cyclo-oxygenase inhibitor indomethacin (150 mg day-1 for three days) or the immunosuppressive agent cyclosporine (5 mg kg-1 body weight for five days). Following administration of nifedipine the rise in plasma concentrations of endothelin-1 during the infusion of the peptide was markedly higher (P less than 0.01) than during control experiments without nifedipine. It is concluded that, in healthy men, nifedipine, indomethacin and cyclosporine do not exert a major influence on the pressor action of endothelin-1. However, nifedipine apparently influences the elimination of endothelin-1 from the circulation in healthy men.
Vierhapper
H
H
I. Medizinische Universitätsklinik, Division of Clinical Endocrinology and Diabetology, Vienna, Austria.
Wagner
O F
OF
Nowotny
P
P
Waldhäusl
W
W
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D015220:Calcium Channels / Q000187:drug effects; D016572:Cyclosporine / Q000008:administration & dosage; D004347:Drug Interactions; D016232:Endothelins / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage*; D011188:Potassium / Q000097:blood
D015220:Calcium Channels; D016232:Endothelins; D016572:Cyclosporine; D009543:Nifedipine; D011188:Potassium; D007213:Indomethacin